Trials / Completed
CompletedNCT03333655
Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy
A Multicenter Study to Explore the Mechanism of Acquired Immune Escape In Patients With Metastatic Cancer Progressing on Checkpoint Inhibitor Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic cancer or hematologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Biopsy | Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies. |
Timeline
- Start date
- 2018-02-16
- Primary completion
- 2022-08-04
- Completion
- 2022-08-04
- First posted
- 2017-11-07
- Last updated
- 2022-08-12
Locations
11 sites across 5 countries: United States, France, South Korea, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT03333655. Inclusion in this directory is not an endorsement.